---
title: "BUZZ-MS resumes Brunello Cucinelli at 'overweight' on 'structurally strong' growth history"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273819250.md"
datetime: "2026-01-27T09:20:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273819250.md)
  - [en](https://longbridge.com/en/news/273819250.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273819250.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273819250.md) | [English](https://longbridge.com/en/news/273819250.md)


# BUZZ-MS resumes Brunello Cucinelli at 'overweight' on 'structurally strong' growth history

Morgan Stanley resumes coverage of Italy’s Brunello Cucinelli (BCU.MI) at “overweight” with PT of 95 euros ($112.59), sees group as “one of the structurally strongest growth stories in luxury”

Group’s structural strengths remain “intact”, as shown by recently reported Q4 sales and “solid” brand momentum, it says

Brunello Cucinelli set to outgrow the luxury sector again in 2026 through an expected 10% revenue growth at constant exchange rates vs 5-6% forecast for the sector, it notes

Concerns over the impact of Brunello Cucinelli’s Saks Global exposure, standing at around 8% of its sales, is “likely overstated” and “should fade as restructuring clarity improves”, it adds

Shares up 0.35% at 80.98 euros on Tues; down 18% YTD and 33% over one year

“The recent price dislocation represents an attractive entry point, rather than a reason to shy away from the premium multiple” - MS

Out of 14 analysts that cover Brunello Cucinelli, 8 rate stock “strong buy” or “buy”, 6 hold - LSEG data ($1 = 0.8437 euros)

## 相關資訊與研究

- [XORTX Confirms Effective Date of Share Consolidation | XRTX Stock News](https://longbridge.com/zh-HK/news/281404463.md)
- [Exclusive-E*Trade in talks to lead SpaceX IPO share sale to small investors in US, sources say](https://longbridge.com/zh-HK/news/281057646.md)
- [3 Promising Penny Stocks With At Least $200M Market Cap](https://longbridge.com/zh-HK/news/281560342.md)
- [Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst⢠(bumetanide nasal spray)](https://longbridge.com/zh-HK/news/281570860.md)
- [Biocon's Ireland-Based Step-Down Subsidiary Rebranded](https://longbridge.com/zh-HK/news/280998444.md)